This month we are highlighting the first clinical trial we have ever funded: Dr. Brady Stein, from Northwestern Memorial Hospital in Chicago is testing a PDL1 Inhibitor. The trial is looking for a few Myelofibrosis patients (particularly those with CALR). If you would like more information, Dr. Stein can be reached at bstein@nmu.edu

In this month's digest we are highlighting some upcoming events for MPN patients and caregivers. There is also an article highlighting some data presented at ASH on Hydroxyurea vs. Interferon. 

Finally, some news you can use: The application deadline for our 2017 request for research proposals is Monday, April 3rd. Once the proposals we receive are reviewed by a committee of MPN researchers, recommendations for funding will be submitted to our Board of Directors. Stay tuned for information about what projects will be funded this year.


Sincerely,

Michelle Woehrle
Executive Director
Participation in clinical trials is the gateway to more treatment options for PV, ET and MF
Cancer drugs fighting a cancerouse cell as a health care medical concept for a pharmaceutical cure to fight the dangerouse disease with life saving medication.
pharmacy2.jpg
Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis
 
The main purpose of this investigational research study is to determine how safe and tolerable the study drug, MEDI4736 (Durvalumab), is in patients with myelofibrosis (MF). The study drug belongs to a group of drugs called immune checkpoint inhibitors, which have shown promise in other forms of cancer, such as melanoma and lung cancer. One of the effects that this drug has is to activate the patient's own natural immune system. For more information contact the Study Coordinator at 312-695-1301 or cancertrials@northwestern.edu 
 
TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea
 
 
This is a Phase 1, open-label, study of TGR-1202, a PI3K delta inhibitor, administered together with ruxolitinib in patients with myeloproliferative neoplasms (specifically: polycythemia vera, primary myelofibrosis, PPV-MF or PET-MF) and MDS/MPN.
 
For more information contact VICC Clinical Trials Information Program 800-811-8480 or click here for the listing on clinicaltrials.gov
 
 

MPN patients who inspire
Against the Odds: Helping Others

  Bob Wanamaker has witnessed the devastating effects of MF both as a triple-negative patient with complications and as a friend to others suffering, and believes that only by helping each other can positive change be realized. Bob was dx'd in Aug '15, and nearly died in Mar '16 when enlarged varices caused by his massive spleen exploded. Upon recuperation, he vowed to help as many patients and their families as he could. Read More

An inspiration in the MPN community

Our Patient spotlight this month shines on Jean who says, "I thought I had fleas" the itching was that bad. I threw out mattresses; and after many appointments with a dermatologist, nothing was found. My daughter told me, 'Mommy nobody else has fleas in our home.'" At the time Jean was unknowingly suffering from pruritus, a common symptom of Polycythemia Vera. 

Events for people with MPN coming to a town near you! 

MPN Advocacy and Education International is hosting educational events for MPN patients around the globe. 

ASH reports on Hydroxyurea vs. Interferon

In case you missed the reports from December / January, catch up now! 



 

DONATE